Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

POMT1 – Muscle-eye-brain Disease

POMT1 encodes protein O-mannosyltransferase 1, essential for α-dystroglycan glycosylation. Biallelic POMT1 variants underlie autosomal recessive muscle-eye-brain disease (MEB), a dystroglycanopathy characterized by congenital muscular dystrophy, ocular defects, and neuronal migration abnormalities.

Autosomal recessive inheritance is supported by segregation of POMT1 variants in multiple families: 13 affected relatives in 5 independent kindreds show concordant biallelic variant transmission, consistent with AR segregation (PMID:31311558).

In a fetal type II lissencephaly series (47 fetuses from 41 unrelated families), POMT1 involvement was demonstrated in 32% of cases, accounting for approximately 15 probands with severe MEB-like phenotypes and pregnancy terminations (PMID:17559086).

A postnatal cohort of 35 patients (27 families) with POMT1-related dystroglycanopathies included one MEB case and delineated a genotype–phenotype correlation: null mutations led to severe Walker–Warburg syndrome or MEB, whereas at least one missense allele yielded milder limb-girdle muscular dystrophy (PMID:31311558).

The variant spectrum encompasses at least nine distinct POMT1 mutations: three missense (e.g., c.598G>C (p.Ala200Pro)), five protein-truncating (nonsense/frameshift), and one canonical splice-site alteration (c.1698+1G>A) identified across MEB and related phenotypes.

Functional assays demonstrate that patient-derived POMT1 mutations abolish O-mannosyltransferase activity when co-expressed with POMT2 in Sf9 cells, confirming a loss-of-function mechanism (PMID:15522202).

Integration of robust genetic and experimental data supports a Strong clinical validity classification for POMT1 in MEB. Early POMT1 testing facilitates definitive diagnosis, genetic counseling, and management of AR dystroglycanopathies.

References

  • Human mutation | 2007 | Molecular heterogeneity in fetal forms of type II lissencephaly. PMID:17559086
  • Orphanet journal of rare diseases | 2019 | Clinical long-time course, novel mutations and genotype-phenotype correlation in a cohort of 27 families with POMT1-related disorders. PMID:31311558
  • Biochemical and biophysical research communications | 2004 | Mutations of the POMT1 gene found in patients with Walker-Warburg syndrome lead to a defect of protein O-mannosylation. PMID:15522202

Evidence Based Scoring (AI generated)

Gene–Disease Association

Strong

50 probands (15 fetal cases in 41 families [PMID:17559086]; 35 patients from 27 families [PMID:31311558]), 13 affected relatives segregating ([PMID:31311558]), concordant functional data showing abrogated O-mannosyltransferase activity [PMID:15522202]

Genetic Evidence

Strong

Biallelic POMT1 variants in ~50 probands across MEB and related dystroglycanopathies; nine distinct pathogenic alleles including three missense and five null mutations

Functional Evidence

Moderate

Patient-derived POMT1 mutations abolish enzymatic activity in POMT1–POMT2 coexpression assays [PMID:15522202]; residual activity correlates with phenotype severity [PMID:31311558]